Comments for SCRX - Stockpickr! Your Source for Stock Ideas

Comments for SCRX

Added By	Comments	Type	Date Added
sarah z	Specialty pharmaceutical company Sciele Pharma Inc. said Monday it has authorized a new share repurchase program of up to $100 million over the next 12 months. Sciele had about 35.6 million shares outstanding as of its latest count with the Securities and Exchange Commission on Oct. 24. The company's existing $40 million buyback, which had about $10 million in shares left to be repurchased, has been canceled. The buyback was set to expire on Aug. 2. The company also recently reported an 11.5 percent decline in net income for the first quarter. The Atlanta-based pharmaceutical company (NASDAQ: SCRX) had net income of $11.5 million on $100.4 million in revenue, compared with net income of $13 million on $82.3 million in revenue in the first quarter of 2007. Earnings were 32 cents a share, compared with earnings of 36 cents a share in the first quarter of 2007. "The first quarter of 2008 marked the launch of four new products for Sciele: the new Sular formulation, Prandin, Fenoglide, and Allegra ODT," said Patrick Fourteau, CEO of Sciele Pharma. "Additionally, in April 2008, Sciele began marketing our fifth new product, the Twinject epinephrine auto-injector for the treatment of severe allergic reactions and anaphylaxis... Products in our Pediatrics, Women's Health and Diabetes businesses are expected to be the key growth drivers for the company this year." During the second half of 2008, the company expects to introduce, upon FDA approval, LARx for the treatment of head lice and MetPrandin for Type II diabetes. It also will launch a new Prenate Elite formulation. The stock trades for 8x cash flow.	Love	May 07, 2008
High Dividends	21.9	Love	April 24, 2008
saxonglass	Pharma - about 10X with growth	Love	March 01, 2008
pinoleropuro	just a hunch	Love	November 04, 2007
parkconsult	Technicals look good	Love	July 18, 2007
Josh Stern	Good valuation for a drug company. Demand for products that threat Type 2 Diabetes and precursors is increasing worldwide.	Love	June 12, 2007
CRAIGE	DRUG	Hate	January 28, 2007
James J. McBuffett	Sells drugs that other companies spend billions to produce. Extremely low sales cost. Flexible.	Love	January 27, 2007